[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"antiplatelet-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:antiplatelet-therapy":37},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,55,112,142,171,198,223],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":39,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":4},"100642101","phase-4-study-of-aspirin-removal-in-patients-supported-by-the-fully-magnetically-levitated-ch-vad-pump-100642101",false,"NCT07644247","STudy of Aspirin Removal in Patients Supported by the Fully Magnetically Levitated CH-VAD Pump","A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled STudy of Aspirin Removal in Patients Supported by the Fully Magnetically Levitated CH-VAD Pump (STAR Trial)","STAR","Inclusion Criteria:\n\n\\-\n\nStudy participants must meet all the following criteria:\n\n1. Age ≥18 years old;\n2. Implanted with the CH-VAD pump for advanced heart failure, and the CH-VAD pump is the first implanted left ventricular assist device;\n3. Able to understand the study purpose, voluntarily participate and sign the informed consent form, and willing to comply with the study procedures and follow-up requirements.\n\nExclusion Criteria:\n\n\\-\n\nStudy participants meet any of the following criteria will be excluded:\n\n1. Requirement for additional temporary or permanent mechanical circulatory support after LVAD implantation;\n2. Requirement for physician-mandated antiplatelet therapy after implantation due to medical history, surgical history, concomitant surgical procedures, or other conditions, including mandated presence or absence of antiplatelet agent;\n3. Occurrence of primary endpoint events prior to randomization (within 2-7 days after implantation);\n4. Inability to take oral medications post-implant through 7 days;\n5. Known allergy to aspirin;\n6. Participation in another clinical investigation that may affect study outcome;\n7. Presence of other comorbid conditions, social or psychological conditions, or other conditions, in the investigator's opinion, that may affect participation in the study or compliance with follow-up requirements.","ALL","18 Years",{"count":20,"type":21},370,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This multi-center, prospective, randomized, double-blinded, placebo-controlled study aims to investigate whether withdrawal of aspirin from the antithrombotic regimen in patients supported with the CH-VAD pump is non-inferior to the standard antithrombotic regimen of vitamin K antagonist combined with aspirin in terms of safety and efficacy.",[27,28,29,30,31,32,33,34,35,36,37,38],"LVAD (Left Ventricular Assist Device) Thrombosis","LVAD","LVAD (Left Ventricular Assist Device)","LVAD-related GI Bleed","Bleeding","Thrombosis","Stroke","Hemocompatibility-related Adverse Event","Ventricular Assist Device","Aspirin","Antiplatelet Therapy","Antithrombotic Therapy",[40,28,33,31,32,41,36,42],"Left ventricular assist device","Hemocompatibility","Antiplatelet","NOT_YET_RECRUITING","2026-06-08",{"date":46,"type":47},"2026-06-12","ACTUAL",{"date":49,"type":21},"2026-06-25",{"date":51,"type":21},"2029-12-31",{"name":53,"class":54},"China National Center for Cardiovascular Diseases","OTHER_GOV",{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":22,"phases":65,"briefSummary":67,"conditions":68,"keywords":74,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":111},"100638421","phase-3-study-of-the-long-term-effects-of-p2y12-inhibitor-monotherapy-and-coagulation-markers-after-percutaneous-coronary-angioplasty-100638421","NCT07582835","Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.","Hunting for the Long-Term EffeCts of P2Y12 Inhibitor monotHerapy and Coagulation Monitoring After PCI: an Open-label, Randomized Study.","HI-TECH 2","Inclusion Criteria:\n\n* Age ≥18 years\n* Prior (≥3 months) ACS and\u002For PCI\n* Eligible for P2Y12 inhibitor monotherapy after an uneventful DAPT course\n* Free from ischemic (i.e. any new episode of ACS, symptomatic restenosis, stent thrombosis, stroke, any revascularization requiring prolonged DAPT) and\u002For bleeding events (defined as BARC ≥ 2) for at least 3 months\n* Written informed consent.\n\nExclusion Criteria:\n\n* Unconscious patients\n* Unable to provide written informed consent\n* Under judicial protection, tutorship or curatorship\n* Unable to understand and follow study-related instructions or unable to comply with study protocol\n* Known hypersensitivity or allergy to clopidogrel, ticagrelor or prasugrel\n* Severe hepatic impairment\n* Haemoglobin level \\\u003C10 g\u002FdL or platelet count \\\u003C100 000 cells\u002FmL\n* Pregnant or breastfeeding women\n* Life expectancy less than 1 year\n* Active participation in another interventional trial\n* Need for concomitant oral anticoagulation\n* History of intracranial haemorrhage (anytime), transient ischemic attack or stroke within 3 months\n* PCI for in-stent restenosis or stent thrombosis at index PCI or within 6 months before randomization",{"count":64,"type":21},355,[66],"PHASE3","Patients who undergo percutaneous coronary intervention (PCI) are commonly treated with antiplatelet therapy to prevent stent thrombosis and recurrence of events. After an initial period of dual antiplatelet therapy, long-term treatment with a single P2Y12 inhibitor (such as clopidogrel, ticagrelor, or prasugrel) is often prescribed. However, the optimal drug and dose for long-term monotherapy remain uncertain, as patients may experience either insufficient platelet inhibition (leading to ischemic events) or excessive inhibition (increasing bleeding risk).\n\nThe HI-TECH 2 study aims to identify the most appropriate type and dose of P2Y12 inhibitor monotherapy to achieve a balanced level of platelet inhibition within a predefined therapeutic range. The study also seeks to better understand how blood coagulation activity evolves over time after PCI.\n\nThis is a prospective, investigator-initiated, single-center, open-label study conducted in two phases. In Phase 1, patients receive stepwise reduced doses of ticagrelor or prasugrel to determine the optimal dose that most consistently achieves the desired level of platelet inhibition. In Phase 2, patients are randomly assigned to receive clopidogrel or the optimal doses of ticagrelor or prasugrel identified in Phase 1.\n\nThe main question of the study is whether optimized ticagrelor or prasugrel regimens are more effective than standard-dose clopidogrel in achieving platelet inhibition within the target therapeutic window, as measured by validated platelet function tests. Additional objectives include evaluating the role of genetic factors in treatment response and assessing markers of coagulation activation over time.\n\nThe results of this study may help personalize long-term antiplatelet therapy after PCI, improving the balance between reducing thrombotic risk and minimizing bleeding complications.",[69,70,71,37,72,73],"Coronary Artery Disease","Percutaneous Coronary Intervention","Acute Coronary Syndromes","Single Antiplatelet Therapy","Coagulation Factors",[69,72,75,76,77,78,79,80,81,82,83,71,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99],"Antiplatelet therapy","Ticagrelor","Prasugrel","Coagulation biomarkers","Clopidogrel","Multiplate","VerifyNow","CYP2C19","ABCB1 gene","Dose optimization","platelet function tests (PFT)","Percutaneous Coronary Intervention (PCI)","High platelet reactivity (HPR)","Low platelet reactivity (LPR)","Bleeding Risk","Ischemic risk","prothrombin fragment F1+2","thrombin-antithrombin (TAT) complex","fibrinopeptide A","fibrinogen","D-dimer","von Willebrand factor activity (VWF)","plasminogen activator inhibitor-1 (PAI-1)","thrombin-activatable fibrinolysis inhibitor (TAFI)","circulating extracellular vesicles","RECRUITING","2026-05-06",{"date":103,"type":47},"2026-05-13",{"date":105,"type":21},"2026-04-20",{"date":107,"type":21},"2028-04",{"name":109,"class":110},"Cardiocentro Ticino","OTHER",1,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":121,"phases":4,"briefSummary":122,"conditions":123,"keywords":125,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":111},"100632536","minimally-invasive-coronary-artery-bypass-supported-by-cangrelor-100632536","NCT07514962","Minimally Invasive Coronary Artery Bypass Supported by Cangrelor","MINOTAUR","Inclusion Criteria for the historical control arm:\n\n* Age ≥18 years old\n* CABG with IMA-LAD graft in MIDCAB technique\n\nInclusion criteria for the prospective arm:\n\n* Age ≥18 years old\n* CABG with IMA-LAD graft in MIDCAB technique\n* Signed informed consent\n\nExclusion criteria for the historical control arm\n\n* Administration of fibrinolytics or GP IIb\u002FIIIa inhibitors\n* Previous intracranial hemorrhage\n* Known bleeding diathesis\n* Patients undergoing concomitant PCI and MIDCAB\n* Severe renal or liver disease\n* Pregnancy or breast feeding\n\nExclusion criteria for the prospective arm\n\n* Unconsciousness\n* Known hypersensitivity to study drug (cangrelor)\n* Recent administration of fibrinolytics or GP IIb\u002FIIIa inhibitors\n* Previous intracranial hemorrhage\n* Known bleeding diathesis\n* Patients undergoing concomitant PCI and MIDCAB\n* Severe renal or liver disease\n* Pregnancy or breast feeding",{"count":120,"type":21},30,"OBSERVATIONAL","The purpose of this study is to find out whether it is safe and practical to perform MIDCAB surgery (a minimally invasive heart bypass procedure) while patients receive a continuous cangrelor infusion during the operation. Cangrelor is a medicine that helps prevent blood clots and works quickly through a vein drip.\n\nThe study compares patients receiving cangrelor during surgery to patients who had the same surgery in the past while on aspirin, with or without cangrelor given beforehand.\n\nStudy Question: Can MIDCAB surgery be safely performed under cangrelor infusion, without increasing the risk of bleeding or other complications?\n\nHypothesis: Using cangrelor during MIDCAB surgery is safe and feasible, and it provides effective protection against blood clots during the procedure.\n\nThis study will help doctors understand whether intraoperative cangrelor can improve patient safety and outcomes in minimally invasive heart surgery.",[69,37,124],"Minimally Invasive Coronary Revascularization Surgery",[126,127,69,128,129,130,131,132,133,89],"Minimally Invasive Direct Coronary Artery Bypass","MIDCAB Surgery","Cangrelor","Perioperative Antiplatelet Therapy","Platelet Function Monitoring","Bridging Therapy","Cardiac Surgery","Intraoperative Antiplatelet Management","2026-04-13",{"date":136,"type":47},"2026-04-14",{"date":138,"type":47},"2024-05-12",{"date":140,"type":21},"2028-01-01",{"name":109,"class":110},{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":17,"minAge":148,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":22,"phases":151,"briefSummary":153,"conditions":154,"keywords":156,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":5},"100623543","discontinuation-of-antiplatelet-therapy-after-drug-coated-balloon-treatment-100623543","NCT07398001","Discontinuation of Antiplatelet Therapy After Drug-Coated Balloon Treatment","Inclusion Criteria:\n\n1. Adults aged 19 years or older who are able to understand the risks, benefits, and treatment alternatives of the study and who provide written informed consent voluntarily.\n2. Patients who underwent drug-coated balloon treatment at least 12 months prior to enrollment.\n3. Patients who have not experienced major adverse cardiovascular events, including myocardial infarction, stroke, or target vessel revascularization, since the index DCB treatment.\n4. Patients who have not experienced major bleeding since the index DCB treatment.\n5. Patients who are receiving antiplatelet therapy at the time of enrollment.\n\nExclusion Criteria:\n\n1. Patients with concomitant vascular disease requiring long-term antiplatelet therapy.\n2. Patients with non-cardiac comorbid conditions that, in the judgment of the investigator, are associated with a life expectancy of less than 1 year or may result in poor compliance with the study protocol.\n3. Patients who are participating in another drug or coronary device clinical study at the time of enrollment.","19 Years",{"count":150,"type":21},1042,[152],"NA","The goal of this clinical trial is to evaluate the benefits and risks of discontinuing antiplatelet therapy on clinical outcomes in patients who previously underwent coronary intervention using a drug-coated balloon.\n\nThe main questions it aims to answer are:\n\nDoes stopping antiplatelet therapy after 12 months affect the risk of net adverse clinical events? Does stopping antiplatelet therapy reduce the risk of bleeding compared with continuing treatment?\n\nResearchers will compare patients who discontinue antiplatelet therapy with patients who continue antiplatelet therapy to determine the impact on clinical outcomes during follow-up.\n\nParticipants will:\n\nBe randomly assigned to either discontinue or continue antiplatelet therapy Receive routine clinical follow-up through clinic visits or telephone contacts Be monitored for cardiovascular events and bleeding outcomes over time",[70,37,155],"Drug-coated Balloon",[157,158,159,160,161],"coronary artery disease","drug-coated balloon","percutaneous coronary intervention","antiplatelet therapy","clinical outcomes","2026-02-02",{"date":164,"type":47},"2026-02-09",{"date":166,"type":21},"2026-02-12",{"date":168,"type":21},"2030-07-31",{"name":170,"class":110},"Ulsan University Hospital",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":17,"minAge":179,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":22,"phases":182,"briefSummary":183,"conditions":184,"keywords":187,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":111},"100605618","phase-3-safety-and-efficacy-of-very-short-dapt-in-older-patients-undergoing-pci-100605618","NCT07164859","Safety and Efficacy of Very Short DAPT in Older Patients Undergoing PCI","Safety and Efficacy of Very Short Dual Antiplatelet Therapy Followed by P2Y12 Inhibitor Monotherapy in Older Patients Undergoing Percutaneous Coronary Intervention (SOLOPCI)","SOLOPCI","Inclusion Criteria:\n\n* Patients ≥ 65 years\n* Successfully treated with percutaneous coronary intervention (PCI) with ≥ 1 drug-eluting stent (final TIMI 3 flow and visually estimated residual diameter stenosis \\\u003C30%) for acute coronary syndrome (including ST-elevation myocardial infarction, non-ST-elevation myocardial infarction and unstable angina) or chronic coronary syndrome (elective PCI). Inclusion is possible after the last PCI procedure in staged procedure.\n* Randomization must be performed before the discharge from the study site.\n* Written informed consent\n* Social security affiliated\n\nExclusion Criteria:\n\n* PCI without drug-eluting stent implantation or with a bioresorbable scaffold\n* Planned coronary artery bypass grafting or cardiac surgery\n* Any planned surgery within 12 months unless intended antiplatelet therapy could be maintained throughout the peri-surgical period\n* Index PCI for stent thrombosis or chronic total occlusion\n* Need for oral anticoagulation therapy\n* Known hypersensitivity or allergy to aspirin, clopidogrel, ticagrelor or prasugrel\n* Use of fibrinolytic therapy within 24 hours of PCI\n* Severe renal insufficiency (MDRD creatinine clearance \\\u003C 30 ml\u002Fmin\u002Fm2) and\u002For dialysis\n* Increased bleeding risk (prior hemorrhagic stroke; stroke \\\u003C 30 days; brain injury\\\u003C6 months; history of intracranial tumor or intracranial hemorrhage; internal bleeding\\\u003C6 weeks; active bleeding; anemia (hemoglobin ≤ 8 g\u002Fdl) or thrombocytopenia (platelets \\\u003C 100 000 G\u002FL); major surgery\\\u003C3 weeks)\n* increased thrombotic risk related to the patient (previous stent thrombosis, ≥ 2 previous myocardial infarction, symptomatic peripheral artery disease, chronic systemic inflammatory disease treated with corticoids or immunosuppressive drug) or the procedure (left main treated, ≥3 stents\u002Ftreated lesions, total length of stents\\>60mm, bifurcation lesion with stents in each branch, stenting of the last patent vessel)\n* Life expectancy less than 1 year\n* Participation in another interventional trial\n* Patients considered as vulnerable by the investigators because of medical, psychological or social conditions:\n\n  * Patients with known or discovered severe cognitive impairment\n  * Patients with treated or untreated severe psychological or psychiatric conditions\n  * Patients with uncorrected severe hearing or visual handicap\n  * Patients with addictive alcohol, drug or substance abuse\n  * Patients with protective measures (guardianship, tutorship, curatorship)\n  * Any other condition considered by the investigators as not warranting informed consent\n* patients with poor quality of the downstream territory with diffuse distal coronary disease\n* women of childbearing potential: non menopaused -with no menses for 12 months without an alternative medical cause- and not permanently sterilized -hysterectomy, bilateral salpingectomy or bilateral oophorectomy-","65 Years",{"count":181,"type":21},1700,[66],"The goal of this clinical trial is to learn if reducing the duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (short treatment regimen, stopping aspirin at day 7) is as safe and efficient as the standard DAPT duration (standard treatment regimen) in elderly patients ≥ 65 years.\n\nThe main questions it aims to answer are:\n\nDoes the reduction of the duration of DAPT reduces rates of bleeding without increasing the risk of cardiovascular events? Researchers will compare a short treatment by DAPT (7 days, followed by single antiplatelet therapy) to a standard treatment duration by DAPT (3 to 12 months) after successful percutaneous coronary intervention with ≥ 1 drug-eluting stent.\n\nParticipants will:\n\n* Take aspirin for 7 days in one group or 3 to 12 months in another group\n* Be contacted by phone at 7 days, 14 days, 21 days, 30 days, 3 months, 6 months and 12 months after hospital discharge\n* Keep a diary of any bleeding or cardiovascular events occurring during the study period",[185,86,37,186],"Coronary Artery Disease (CAD)","Elderly (People Aged 65 or More)",[160,159,188],"elderly","2025-09-25",{"date":191,"type":47},"2025-10-01",{"date":193,"type":21},"2025-10",{"date":195,"type":21},"2029-10",{"name":197,"class":110},"Vincent ROULE",{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":22,"phases":207,"briefSummary":208,"conditions":209,"keywords":211,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":111},"100410422","phase-4-early-antiplatelet-therapy-after-hemorrhagic-infarction-in-acute-ischemic-stroke-treated-with-intravenous-thrombolysis-hits-100410422","NCT04624295","Early Antiplatelet Therapy After Hemorrhagic Infarction in Acute Ischemic Stroke Treated With Intravenous Thrombolysis (HITs)","Early Antiplatelet Therapy After Hemorrhagic Infarction in Acute Ischemic Stroke Treated With Intravenous Thrombolysis in China (HITs)：a Randomized Clinical Trial","Inclusion Criteria:\n\n1. Acute ischemic patients receiving intravenous thrombolysis within 24 hours upon stroke onset\n2. Be confirmed as Hemorrhagic Infarction at 24 to 36 hours after intravenous thrombolysis by computerized tomography\n3. The patient or family member signed an informed consent\n\nExclusion Criteria:\n\n1. Early use of anticoagulant drugs within 1 week after intravenous thrombolysis;\n2. Tirofiban was used after receiving endovascular treatment;\n3. Intraoperative stent placement after receiving endovascular treatment;\n4. Subarachnoid hemorrhage or ventricular hemorrhage;\n5. There are contraindications for aspirin use;",{"count":206,"type":21},294,[24],"Previous study showed that the proportions of hemorrhagic Infarction after intravenous thrombolysis were 24.2% and 32.5% in the control group and the alteplase group, and most of them were asymptomatic. Hemorrhagic Infarction was a part of the natural progression after acute ischemic stroke. Previous study have shown no significant relationship between hemorrhagic Infarction and poor outcome in acute ischemic stroke (AIS) patients. In this study, a randomized controlled trial will be conducted to explore the efficacy and safety of early antiplatelet therapy after hemorrhagic infarction in acute ischemic stroke treated with intravenous thrombolysis.",[37,210],"Hemorrhagic Infarction",[212,213,210,160],"acute ischemic stroke","intravenous thrombolysis","2025-06-11",{"date":216,"type":47},"2025-06-15",{"date":218,"type":47},"2021-01-01",{"date":220,"type":21},"2026-06-30",{"name":222,"class":110},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":22,"phases":233,"briefSummary":234,"conditions":235,"keywords":237,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":251},"100569794","mce-identifying-bleeding-lesions-in-patients-with-antiplatelet-drugs-related-acute-non-hematochezia-gastrointestinal-bleeding-100569794","NCT06698874","MCE Identifying Bleeding Lesions in Patients with Antiplatelet Drugs-Related Acute Non-Hematochezia Gastrointestinal Bleeding","Diagnostic Efficacy of Magnetically Controlled Capsule Endoscopy (MCE) for Identification of Bleeding Lesions in Patients with Antiplatelet Drugs-Related Acute Non-Hematochezia Gastrointestinal Bleeding：Prospective, Multicenter Study","MCE","Inclusion Criteria:\n\n1. No gender limit, age ≥ 18 years；\n2. Acute non-hematochezia gastrointestinal bleeding symptoms, including haematemesis or melena；\n3. Taking antiplatelet drugs continuously for at least 14 days；\n4. Hemodynamically stable；\n5. Able to provide informed consent.\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years；\n2. Hemodynamically unstable even after initial volume resuscitation and\u002For have ongoing fresh hematemesis at presentation；\n3. With upper gastrointestinal bleeding caused by peptic ulcer or acute gastric mucosal lesion within 1 month before inclusion；\n4. History of endoscopic therapy (such as ESD, EMR, etc.) within 1 month before inclusion；\n5. Gastrointestinal tumor, decompensation of cirrhosis with esophageal or gastric varices；\n6. Haematopathy and bleeding tendency；\n7. Patients who have no surgical conditions or refuse to undergo any abdominal surgery (once the capsule is stuck, it cannot be removed surgically)；\n8. Pacemaker or other implanted electromedical devices which could interfere with magnetic resonance；\n9. Patients plan to undergo magnetic resonance imaging examination before excretion of the capsule；\n10. Suspected or known intestinal stenosis or other known risk factors for capsule retention.\n11. Pregnancy；\n12. Dysphagia；\n13. With and conditon contraindicated to ds-MCE or EGD；\n14. With and conditon that is not suitable for participation in the study evaluated by researchers.",{"count":232,"type":21},204,[152],"The goal of this clinical trial is to explore the diagnostic efficacy of detachable string magnetically controlled capsule endoscopy (ds-MCE) for identification of bleeding lesions in patients with antiplatelet drugs-related acute non-hematochezia gastrointestinal bleeding. The main questions it aims to answer are:\n\nCompared to the conventional esophagogastroduodenoscopy, does ds-MCE accurately detect bleeding lesions in the upper gastrointestinal tract in patients with antiplatelet drugs-related acute non-hematochezia gastrointestinal bleeding? Recording bleeding lesions in the small bowel detected by ds-MCE in patients with antiplatelet drugs-related acute non-hematochezia gastrointestinal bleeding.\n\nParticipants will:\n\nUndergo ds-MCE first and subsequently EGD within 24 hours. Receive follow-up in the following 30days.",[236,37],"Gastrointestinal Bleeding",[238,239,240,241],"magnetically controlled capsule endoscopy","string","antiplatelet drugs","gastrointestinal bleeding","2024-11-20",{"date":244,"type":47},"2024-11-21",{"date":246,"type":21},"2024-12-01",{"date":248,"type":21},"2026-12-30",{"name":250,"class":110},"Changhai Hospital",4]